We are live on ! Find out more
TSVT

2seventy bio

Delisted

TSVT was delisted on the 13th of May, 2025.

141 hedge funds and large institutions have $317M invested in 2seventy bio in 2022 Q4 according to their latest regulatory filings, with 30 funds opening new positions, 40 increasing their positions, 32 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

148% more call options, than puts

Call options by funds: $500K | Put options by funds: $202K

58% more first-time investments, than exits

New positions opened: 30 | Existing positions closed: 19

25% more repeat investments, than reductions

Existing positions increased: 40 | Existing positions reduced: 32

6% more funds holding

Funds holding: 133141 (+8)

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

34% less capital invested

Capital invested by funds: $478M → $317M (-$161M)

Holders
141
Holders Change
+8
Holders Change %
+6.02%
% of All Funds
2.27%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
30
Increased
40
Reduced
32
Closed
19
Calls
$500K
Puts
$202K
Net Calls
+$298K
Net Calls Change
-$1.41M
Name Holding Trade Value Shares
Change
Change in
Stake
SO
151
STRS Ohio
Ohio
-$23K -1,600 Closed
Macquarie Group
152
Macquarie Group
Australia
-$6K -332 Closed
IA
153
IFP Advisors
Florida
-$7K -152 Closed
LC
154
Lindbrook Capital
California
-$1.31K -93 Closed

TSVT Hedge Fund Activity: Q4 2022 in Review

141 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in 2seventy bio (TSVT) for Q4 2022, worth a combined $317M — down 34% from $478M a quarter earlier.

Buyers outnumbered sellers: 30 funds opened new TSVT positions and 19 closed out — a net gain of 11 holders — while 40 added to existing stakes and 32 trimmed.

The largest buyer was Casdin Capital, adding an estimated $17.4M. The largest seller was Armistice Capital, exiting entirely with an estimated $18.4M sold.

  • 141 institutional investors held 2seventy bio (TSVT) as of Q4 2022, up from 133 in Q3 2022.
  • Funds reported $317M of 2seventy bio stock for Q4 2022, down 34% quarter-over-quarter.
  • 30 funds opened new 2seventy bio positions in Q4 2022 and 19 closed out, a net change of +11 holders.
  • The largest 2seventy bio buyer in Q4 2022 was Casdin Capital, an estimated $17.4M added.
  • The largest 2seventy bio seller in Q4 2022 was Armistice Capital, an estimated $18.4M sold.

Based on aggregated 13F filings for Q4 2022.